HLS Therapeutics Inc
TSX:HLS
Intrinsic Value
HLS Therapeutics, Inc. operates as a pharmaceutical company. [ Read More ]
The intrinsic value of one
HLS
stock under the Base Case scenario is
11.82
CAD.
Compared to the current market price of 4.95 CAD,
HLS Therapeutics Inc
is
Undervalued by 58%.
HLS Therapeutics Inc's market capitalization is 158.3m CAD.
HLS stock price is 4.95 CAD.
HLS stock price (4.95 CAD) is 58% less than its Intrinsic Value (11.82 CAD).
HLS has upside potential of 49% compared to the average analyst price target.
Open Wall St Estimates
HLS's Revenue has grown by 3% over the past 12 months.
HLS's ROIC (Return on Invested Capital) has decreased in the last 3 years from -5% to -6%, and is approaching profitability.
HLS's Revenue has been growing by 4% per year for the last 3 years.
HLS's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
HLS's D/E (Debt to Equity) is very low and is equal to 0.84.
HLS's ROE (Return on Equity) has significantly decreased in the last 3 years from -12% to -25%, and is approaching profitability.
HLS has positive Free Cash Flow for the last twelve months.
HLS's short-term assets (44m USD) exceed its short-term liabilties (27m USD).
HLS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -6%.
HLS's long-term assets (209m USD) exceed its long-term liabilties (111m USD).
HLS has negative Operating Income for the last twelve months.
HLS has negative Net Income for the last twelve months.
HLS's ROE (Return on Equity) for the past 12 months is negative and is equal to -25%.
HLS has positive Net Debt. This means that the company has more debt (82m USD) than cash and short-term investments (22m USD).
HLS has negative three-year average ROIC (Return on Invested Capital): -5%. The company is not efficient at using invested capital to generate operating income.
HLS has positive Gross Profit for the last twelve months.
HLS has negative three-year average ROE (Return on Equity): -14%. The company is not efficient at transforming stockholders' equity into net income.
HLS's Altman Z-Score is very low and is equal to -0.41.
Valuation Backtest
HLS Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
HLS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
HLS Therapeutics Inc
Balance Sheet Decomposition
HLS Therapeutics Inc
| Current Assets | 44.1m |
| Cash & Short-Term Investments | 22m |
| Receivables | 10.7m |
| Other Current Assets | 11.4m |
| Non-Current Assets | 165m |
| PP&E | 965k |
| Intangibles | 162.3m |
| Other Non-Current Assets | 1.7m |
| Current Liabilities | 26.7m |
| Accounts Payable | 14.1m |
| Other Current Liabilities | 12.6m |
| Non-Current Liabilities | 84.7m |
| Long-Term Debt | 82.5m |
| Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
HLS Therapeutics Inc
|
Revenue
|
63.1m
USD
|
|
Cost of Revenue
|
-7.6m
USD
|
|
Gross Profit
|
55.5m
USD
|
|
Operating Expenses
|
-67.3m
USD
|
|
Operating Income
|
-11.8m
USD
|
|
Other Expenses
|
-15.7m
USD
|
|
Net Income
|
-27.5m
USD
|
Free Cash Flow Analysis
HLS Therapeutics Inc
What is Free Cash Flow?
HLS Profitability Score
Profitability Due Diligence
HLS Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
HLS Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
HLS Solvency Score
Solvency Due Diligence
HLS Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
HLS Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HLS Price Targets Summary
HLS Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
HLS
is 7.37 CAD
with a low forecast of 4.19 CAD and a high forecast of 11.03 CAD.
Shareholder Return
HLS Price
HLS Therapeutics Inc
| Average Annual Return | -5.86% |
| Standard Deviation of Annual Returns | 37.9% |
| Max Drawdown | -86% |
| Market Capitalization | 158.3m CAD |
| Shares Outstanding | 31 921 300 |
| Percentage of Shares Shorted | 1.26% |
Company Profile
HLS Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
Contact
IPO
Employees
Officers
The intrinsic value of one
HLS
stock under the Base Case scenario is
11.82
CAD.
Compared to the current market price of 4.95 CAD,
HLS Therapeutics Inc
is
Undervalued by 58%.
You don't have any saved screeners yet
